ロード中...
Driving toward targeted therapy for LCH
In this issue of Blood, Brown et al identify somatic mutations of MAP2K1 capable of driving the RAS-RAF-MEK-ERK pathway in Langerhans cell histiocytosis (LCH). Their findings lend important insight into the pathogenesis of this disease and provide the rationale for exploring targeted approaches in c...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Hematology
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4155264/ https://ncbi.nlm.nih.gov/pubmed/25190750 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-07-587378 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|